本帖最后由 老马 于 2013-3-13 13:43 编辑
& G, C; u' R: x6 M: r
+ I! s& y2 }" ^1 B健择（吉西他滨）+顺铂+阿瓦斯汀
( L/ o! s, [* e8 @, a# F0 h0 h Gemzar +Cisplatin + Avastin9 z& O; t3 V2 u6 B
http://annonc.oxfordjournals.org/content/21/9/1804.full
) e5 z; Y+ t2 O0 L" TOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
' g2 h3 V5 \6 m$ HPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 K- ^# _2 {! b2 [/ {$ s7 TResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
4 {$ G# S6 j, R5 s4 ^0 p( w
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1035)
! b. q+ f+ l8 R z华为网盘附件：
* |9 `. n; O8 O! Y【华为网盘】ava.JPG
+ H% P% y3 L: {8 }7 y. y- k' E. h( Z |
显身卡
